Cipla and Roche settled patent dispute last year. Cipla withdrew its petition in Supreme Court against in the matter.
Lara Bezerra, Managing Director – Roche Pharma India said: “This partnership will significantly advance our efforts to expand the reach of, and improve access to, our innovative medicines. This will also enable us at Roche to focus on bringing new, transformative medicines to patients in India. As Roche, we will continue to collaborate with various stakeholders to help transform healthcare in India.”
Avastin which is brand name of biologic drug Bevacizumab was introduced in India in 2005. It is a blockbuster drug for Roche and earned over $ 7 billion for the drug maker two years ago. Local drug makers Intas, Zydus Cadila, Hetero and Reliance LifeSciences sell copies of Bevacizumab in the domestic market.
Cipla's managing director Umang Vohra said the prevalence of cancer and rheumatoid arthritis is widely spread across India and Cipla can contribute to provide broader access to innovative medicines.